Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients by unknown
RESEARCH ARTICLE Open Access
Comparison of the HER2, estrogen and
progesterone receptor expression profile of
primary tumor, metastases and circulating
tumor cells in metastatic breast cancer
patients
Bahriye Aktas1*, Sabine Kasimir-Bauer1, Volkmar Müller2, Wolfgang Janni3, Tanja Fehm4, Diethelm Wallwiener5,
Klaus Pantel6, Mitra Tewes7 and on behalf of the DETECT Study Group
Abstract
Background: The expression of HER2, estrogen (ER) and progesterone (PR) receptor can change during the course
of the disease in breast cancer (BC). Therefore, reassessment of these markers at the time of disease progression
might help to optimize treatment decisions. In this context, characterization of circulating tumor cells (CTCs) could
be of relevance since metastatic tissue may be difficult to obtain for repeated analysis. Here we compared HER2/ER/
PR expression profiles of primary tumors, metastases and CTCs.
Methods: Ninety-six patients with metastatic BC from seven University BC Centers in Germany were enrolled in this
study. Blood was obtained at the time of first diagnosis of metastatic disease or disease progression and analyzed
for CTCs using the AdnaTest BreastCancer (QIAGEN Hannover GmbH, Germany) for the expression of EpCAM, MUC-1,
HER2, ER and PR. HER2 expression on CTCs was additionally assessed by immunocytochemistry using the
CellSearch® assay.
Results: The detection rate for CTCs using the AdnaTest was 43 % (36/84 patients) with the expression rates of
50 % for HER2 (18/36 patients), 19 % for ER (7/36 patients) and 8 % for PR (3/36 patients), respectively. Primary
tumors and CTCs displayed a concordant HER2, ER and PR status in 59 % (p = 0.262), 39 % (p = 0.51) and
44 % (p = 0.62) of cases, respectively. For metastases and CTCs, the concordance values were 67 % for HER2
(p = 0.04), 43 % for ER (p = 0.16) and 46 % for PR (p = 0.6). Using the CellSearch® assay, the CTC-positivity rate
was 53 % (42/79 patients) with HER2 expressed in 29 % (12/42) of the patients. No significant concordance
(58 % and 53 %) was found when HER2 on CTCs was compared with HER2 on primary tumors (p = 0.24) and
metastases (p = 0.34). Interestingly, primary tumors and metastases were highly concordant for HER2 (84 %, p = 1.13E-
08), ER (90 %, p = 3.26E-10) and PR (83 %, p = 2.09E-09) and ER-and PR-positive metastases were significantly found to
be of visceral origin (p = 0.03, p = 0.02).
Conclusion: Here we demonstrate that the molecular detection of HER2 overexpression in CTC is predictive of the
HER2 status on metastases. Detailed analysis of ER and PR expression rates in tissue samples and CTCs may provide
useful information for making treatment decisions.
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Background
In primary and metastatic breast cancer (MBC), tumors
are usually analyzed for the presence or absence of the
estrogen receptor (ER), the progesterone receptor (PR),
and for amplification of HER-2, and the results of these
analyses direct the types of treatment that patients re-
ceive. In MBC, patients may be treated with systemic
therapy (chemotherapy, biological therapy, targeted ther-
apy, hormonal therapy), local therapy (surgery, radiation
therapy), or a combination of these treatments. The
choice of treatment generally depends on the character-
istics of the primary tumor because metastatic tissue is
often difficult to obtain. Notably, HER-2 as well as ER/
PR were shown to be differentially expressed between
the primary tumor and corresponding metastases in up
to 48 % which might lead to ineffective treatment in the
absence of the respective marker [1–6]. Therefore, re-
assessment of these markers at the time of disease pro-
gression might help to optimize treatment decisions.
Although biopsies from most metastatic sites may be ob-
tained by the use of imaging and interventional radi-
ology on a routine basis, these techniques are invasive
and may pose some discomfort or may result in compli-
cations. Thus, a blood based biomarker would be desir-
able to bypass these problems.
In this regard, circulating tumor cells (CTCs) would
be an ideal ‘surrogate tissue’ to identify prognostic and
predictive factors that will help in selecting the optimal
therapeutic strategy for each individual patient in case
that metastatic tissue is not available.
Our study group has already demonstrated that ER
and PR were differentially expressed between primary
tumor and CTCs in MBC [7]. It was the purpose of the
present study to compare the HER2/ER/PR expression
profile of primary tumor and metastases, primary tumor
and CTCs as well as metastases and CTCs. To our
knowledge, it is the first study comparing histopatho-
logical and molecular findings between primary tumor,
metastases and CTCs.
Methods
Patients and study design
A total of 96 MBC cancer patients, from seven Univer-
sity Breast Cancer Centers [Essen (n = 62), Düsseldorf
(n = 6), Erlangen (n = 3), Hamburg (n = 10), Heidelberg
(n = 5), Muenchen (n = 3), Regensburg (n = 2) and
Tuebingen (n = 5)] in Germany were enrolled in this
prospective open non-randomized study from 12/2007
until 04/2009. In general, most patients (69 %) had
ductal breast cancer, moderately and poorly differenti-
ated tumors were predominant. 73 % of the primary tu-
mors were ER-, 55 % were PR-positive and 33 % had an
overexpression of HER2 (Dako score 3+). Biopsies of
metastases were taken from visceral (63 %) and non-
visceral sites (37 %). Patients received different chemo-
therapeutic treatments in different lines of metastatic
settings including anthracyclines, taxanes, capecitabine,
vinorelbine and 5-FU or endocrine treatment including
Tamoxifen, aromatase inhibitors and Fulvestrant (data
not shown). CTCs from these patients were analyzed for
ER/PR/HER2 expression during palliative therapy to
compare these results with receptor expression on the
primary tumor and metastases.
Eligibility criteria
The eligibility criteria were as follows: Epithelial invasive
carcinoma of the breast with distant metastatic disease
(M1), age ≥ 18 years, first diagnosis of metastatic disease
or disease progression (before start of new treatment regi-
men). Prior adjuvant treatment, radiation or any other
treatment of metastatic disease were permitted.
Exclusion criterion was secondary primary malignancy
(except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin). Blood was
drawn before the start of a new line of therapy. A web-
based databank was designed for data management and
online-documentation (www.detetct-study.de). All speci-
mens were obtained after written informed consent and
collected using protocols approved by the institutional
review board (2007/B01).
Enrichment and molecular characterization of CTCs using
the AdnaTest BreastCancer Kits
Two 5 ml EDTA blood samples were collected for isola-
tion of CTCs using the AdnaCollect blood collection tubes
(QIAGEN Hannover GmbH, Langenhagen, Germany) and
stored at 4 °C until further examination. In-house samples
were processed immediately or not later than 4 h after
blood withdrawal, shipped samples were processed within
24 h. Establishment and validation of the AdnaTest Breast-
Cancer assay has been described in detail elsewhere [7–9].
Briefly, all samples were subjected to immunomagnetic
enrichment of CTCs using the AdnaTest BreastCancer-
Select kit (QIAGEN Hannover GmbH, Langenhagen,
Germany) followed by RNA isolation and subsequent
gene expression analysis [EpCAM (GA733-2), MUC-1,
HER2] by reverse transcription and Multiplex-PCR
(polymerase chain reaction) in separated tumor cells
using the The AdnaTest BreastCancerDetect (QIAGEN
Hannover GmbH, Langenhagen, Germany) according to
the instructions provided with the kit. Expression of ER
and PR was assessed in an additional single-plex RT-PCR.
Visualization of the PCR fragments was carried out with a
2100 Bioanalyzer using the DNA 1000 LabChips (Agilent
Technologies) and the Expert Software Package (version
B.02.03.SI307) both Böblingen, Germany. The primers
generate fragments of the following sizes: GA 733–2: 395
Aktas et al. BMC Cancer  (2016) 16:522 Page 2 of 8
base pairs (bp), MUC1: 293 bp, HER2: 270 bp, PR: 270 bp,
ER: 305 bp, and actin: 114 bp.
Evaluation of data
The test is considered positive if a PCR fragment of at
least one tumor associated transcript (MUC-1, GA 773–
2 or HER2) is clearly detected. Peaks with a concentra-
tion of > 0.15 ng/μl are positive for the transcripts
GA733-2, MUC1 and HER2. Peaks that are not detected
at the above setting are negative (concentration of <
0.15 ng/μl). Peaks with a concentration of > 0.60 ng/μl
are positive for the ER transcript and the PR expression
is considered positive when the transcript is detected
without applying any cut-off.
Determination of HER2-expression using the CellSearch
assay
Two 7.5 ml blood samples were collected into CellSave
tubes (Veridex Inc.) for the CellSearch assay and sent at
room temperature based on the manufacturer’s recom-
mendation. Blood samples not processed within 96 h for
the CellSearch assay were discarded. A validation study
demonstrated that the samples could be stored and
transported (up to 72 h) and showed high inter- and
intra-assay concordance of the results in a multicenter
setting [10].
In brief, CTCs are captured from peripheral blood by
anti-EpCAM-antibody-bearing ferrofluid and identified by
cytokeratin-positivity, negativity for the leukocyte common
antigen CD45 and DAPI staining to ensure the integrity of
the nucleus. HER2 expression of CTCs was characterized
within the Cell Search system by addition of a FITC (Fluor-
escein isothiocyanate)-labeled anti-HER2 antibody (Cell-
Search© tumor phenotyping reagent HER2/neu, Veridex,
Raritan, NJ) as described previously [11]. The intensity of
the HER2-specific immunofluorescence was categorized as
negative (0), weak (1+), moderate (2+) and strong (3+).
CTCs were considered HER2 positive if at least one CTC
had a strong HER2 staining (3+).
Immunohistochemical analysis of the primary tumor and
metastases
The ER, PR and HER2 status of the primary tumor was
obtained from the patients` charts. In all participating
centers, the HER2 status has been determined by the
HERCEP™ test (Dako, Glostrup, Denmark) and/or the
Pathvysion-kit (HER2/neu) (Vysis, Downers Grove, IL).
All pathology laboratories had participated in ring ex-
periments and were certified laboratories for ER, PR and
HER2 detection. A central review of the ER, PR and
HER2 status of the primary tumor as well as the metas-
tases was, therefore, not performed.
Statistical analysis
Concordance of the results between the different methods
[AdnaTest (HER2;ER;PR), CellSearch (HER2) and tissue
IHC for HER2, ER and PR] was evaluated using cross
tabulation combined with Fisher’s exact-test. The compari-
son of the primary tissue and the metastatic tissue pheno-
type with regards to HER2, ER and PR was analyzed
accordingly. WinSTAT® for Microsoft®Excel version 2012.1
(www.winstat.de) was used for the statistical calculations.
Null hypothesis of discordant results was rejected
when p-values were ≤ 0.05.
Results
Detection of CTCs
The detection rate for CTCs as determined by the
AdnaTest and the CellSearch assay are demonstrated in
Fig. 1. The AdnaTest could be applied in 84/96 patients
(88 %) and resulted in an overall CTC detection rate of
43 % (36/84 patients) with the expression of 50 % (18/36
patients) for HER2 and EpCAM, 61 % for MUC-1 (22/
36 patients), 19 % for ER (7/36 patients) and 8 % for PR
(3/36 patients), respectively. Applying the CellSearch®
assay for CTC detection in 79/96 (82 %) of patients, the
CTC-positivity rate was 53 % (42/79 patients) with the
expression rate of 29 % for HER2 (12/42 patients). Since
the CellSearch system is based on immunomagnetic













CTC results for AdnaTest and CellSearch
in
 %
CTC-AdnaTest EpCAM MUC1 HER2 ER PR CTC-CellSearch HER2
Fig. 1 Results for CTCs obtained by the AdnaTest Breast Cancer and the CellSearch Assay
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EpCAM capturing, a direct comparison of EpCAM-
positive CTCs as detected by both test systems was per-
formed. A comparison for EpCAM was feasible in 38 pa-
tients. The AdnaTest BreastCancer only detected 8 of 38
EpCAM-positive cases as evaluated by CellSearch. On
the other hand, in the 37 CellSearch-negative cases, the
AdnaTest detected 15 positive cases with the expression
rates of 40 % for EpCAM and HER2 (both 6/15 patients)
and 76 % for MUC-1 (11/15 patients), data not shown.
Comparisons of expression profiles on CTCs with those
on tissue samples
Comparisons of the expression profiles of ER, PR and
HER2 on CTCs with those on tissue samples were only
performed in CTC-positive patients. A comparison for
HER2 was done applying the CellSearch® assay and the
AdnaTest Breast Cancer. Due to technical requirements
of both assays, a comparison of ER and PR was only
feasible using the AdnaTest BreastCancer. All compari-
son studies are documented in Table 1.
Applying the AdnaTest BreastCancer, primary tumors
and CTCs displayed a concordant HER2, ER and PR sta-
tus in 59 % (p = 0.262), 39 % (p = 0.51) and 44 % (p = 0.62)
of cases, respectively. For metastases and CTCs, the con-
cordance values were 67 % for HER2 (p = 0.04), 43 % for
ER (p = 0.16) and 46 % for PR (p = 0.6). Interestingly, in
26/36 patients with ER/PR-positive metastases, CTCs
were positive in 27 % of cases and in the other 10 ER/PR-
negative patients, the concordance was 100 % (p = 0.066).
Applying the CellSearch® assay, no significant concord-
ance (58 % and 53 %) was found when HER2 status on
CTCs was compared with HER2 expression on primary
tumors (p = 0.41) and on metastases (p = 0.52).
Comparing the expression of the predictive markers on
primary tumor and metastases, a high concordance was
displayed for ER (90 %, p = 3.26E-10), PR (83 %, p = 2.09E-
09) and HER2 (84 %, p = 1.13E-08). These results were
confirmed when concordances for ER, PR and HER2 were
only calculated in CTC-positive samples (ER: p = 7.2E-10;
PR: p = 6.23E-10 and HER2: p = 0.001).
Direction of concordance/discordance in the expression
of ER, PR and HER2
As already described above, these analyses were only
feasible using the results obtained with the AdnaTest
Breast Cancer. As apparent from Table 2, a loss of re-
ceptor expression on CTCs can be seen for ER and PR
when compared to the expression on primary tumors
and on metastases. In contrast, although not significant,
a trend for vice versa behaviour with regard to HER2 ex-
pression can be obtained for a substantial number of
patients.
Influence of the type of metastatic lesion on concordance
Table 3 illustrates the expression of predictive markers
with regard to visceral (ML1) and bone (ML2) metasta-
sis. Although not significant, visceral metastasis is more
likely found in ER- as well as PR-positive tumors
whereas no difference can be obtained for HER2. Inter-
estingly, when these analyses were performed for metas-
tases, ER- and PR-positive metastases significantly were
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found to be of visceral origin (p = 0.03; p = 0.02) whereas
no trend was seen for HER2.
Discussion
In MBC, the choice of therapy generally depends on the
size, location, and number of metastatic sites whereas
the decision to administer antihormonal- and/or HER2-
targeted therapy depends on the expression of these
markers on the primary tumor since metastatic tissue is
often difficult to obtain. However, several BC studies have
indicated that the expression of HER2, ER and PR can
change during course of disease [1–6, 12–30]. Therefore,
reassessment of the predictive markers at the time of dis-
ease progression might help to optimize treatment deci-
sions. In this context, characterization of CTCs could be
of relevance in the future.
Here we demonstrate that the molecular detection of
HER2 overexpression in CTCs using the AdnaTest
BreastCancer is able to significantly predict the HER2
status on metastases. However, for ER/PR, a more de-
tailed analysis of expression rates in tissue samples will
be necessary to decide whether to use CTCs as a useful
tool for treatment decisions. Interestingly, in contrast to
some already published studies [1–6, 12–30], we could
show that primary tumors and their metastases showed
a highly significant concordance of the expression of
predictive markers. Furthermore, ER- and PR-positive
metastases significantly were found to be of visceral ori-
gin whereas no trend was seen for HER2 which has to
be discussed in more detail.
Table 2 Direction of the concordance/discordance in the
expression of ER, PR and HER2
a) ER Tumor ER- Tumor ER+
AdnaTest ER- 10 21
AdnaTest ER+ 1 4
Fishers exact Test: p = 0,51
Metastases ER- Metastases ER+
AdnaTest ER- 10 20
AdnaTest ER+ 0 5
Fishers exact Test: p = 0,16
Metastases ER- Metastases ER+
Tumor ER- 9 19
Tumor ER+ 1 2
Fishers exact Test: p = 7,2E-6
b) PR Tumor PR- Tumor PR+
AdnaTest PR- 14 19
AdnaTest PR+ 1 2
Fishers exact Test: p = 0,62
Metastases PR- Metastases PR+
AdnaTest PR- 14 18
AdnaTest PR+ 1 2
Fishers exact Test: p = 0,60
Metastases PR- Metastases PR+
Tumor PR- 13 2
Tumor PR+ 2 18
Fishers exact Test: p = 6,23E-6
c)HER2 Tumor HER2- Tumor HER2+
AdnaTest HER2- 12 6
AdnaTest HER2+ 8 8
Fishers exact Test: p = 0,043
Metastases HER2- Metastases HER2+
AdnaTest HER2- 14 4
AdnaTest HER2+ 8 10
Fishers exact Test: p = 0,043
Metastases HER2- Metastases HER2+
Tumor HER2- 17 3
Tumor HER2+ 4 10
Table 3 Expression of predictive markers on primary tumor and
metastases with regard to visceral (ML1) and bone (ML2) metastasis
ML1 ML2
Tumor ER- 6 8
Tumor ER+ 32 15
Fischers exact Test: p = 0,08
ML1 ML2
Tumor PR- 13 13
Tumor PR+ 25 10
Fishers exact Test: p = 0,08
ML1 ML2
Tumor Her2- 22 15
Tumor Her2+ 11 7
Fishers exact Test: p = 0,9
ML1 ML2
Metastases ER- 6 9
Metastases ER+ 33 14
Fishers exact Test: p = 0,03
ML1 ML2
Metastases PR- 16 16
Metastases PR+ 23 7
Fishers exact Test: p = 0,02
ML1 ML2
Metastases Her2- 23 16
Metastases Her2+ 16 7
Fishers exact Test: p = 0,4
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In a prospective study, Simmons et al. demonstrated a
discordant ER/PR and HER2 status in 40 % and 8 % of
cases in more than half of the 40 patients analyzed who
presented with new lesions suspicious for MBC. Conse-
quently, therapeutic intervention was changed accordingly
in 20 % of the patients who agreed to undergo biopsy not
only to confirm their metastatic phenotype but also to
have reassurance of receiving “targeted therapy” [3]. An-
other MBC study including 25 patients with liver metasta-
ses observed a discordant ER, PR and HER2 receptor
status in 14.5 %, 48.6 % and 13.9 % of cases, respectively,
which led to change in therapy in 12.1 % of patients [2].
With regard to HER2, subsequently published studies have
reported discordant rates from 1 % to 24 % between pri-
mary tumor and metastases [1, 2, 12–29] and a study-level
meta-analysis including 26 trials and about 2.500 patients,
found a discordance rate for either HER2 loss or gain of
5.5 % [30, 31]. These findings are quite in opposite to our
study, showing a significantly high concordance for these
markers when comparing primary tumor and metastases.
A discordant expression of these receptors and the pri-
mary tumor and corresponding metastases and/or CTCs
has already been demonstrated with a discordance between
primary BC and HER2 expression on CTCs in the setting
of disease recurrence at variable rates, with a gain of HER2
from 9 % to over 60 % in different studies [32–39]. The fact
that ER and PR were differentially expressed between pri-
mary tumor and CTCs confirms the results of our previ-
ously published study demonstrating a loss of receptor
expression on CTCs when compared with the expression
on primary tumors [7]. These results can now be extended
and confirmed for metastases and CTCs. However, the
concordance for biomarker negativity seems to be higher
in this study, although the number of these cases is quite
small. In fact, the possibility of changes in receptor status
during the course of tumor progression in triple-negative
BC is very low, up to 8 %, despite changes in receptor posi-
tive BC with up to 40 % [40]. One could speculate that es-
cape from antitumor therapy is more effective for CTCs
when losing ER and PR on the surface.
In addition, the fact that ER- and PR-positive metasta-
ses significantly were found to be of visceral origin with
a positive trend also documented in primary disease al-
lows the hypothesis that CTC release as well as their
downregulation of hormonal receptors might be recog-
nized as a resistance mechanism to adjuvant endocrine
therapy. As a consequence, CTCs released under therapy
downregulate the therapeutic target during their phase
of epithelial-mesenchymal transition (EMT) but recover
ER/PR overexpression during the course of metastasis.
This could fairly explain how hormone receptor positive
visceral metastasis appear in significant concordance to
the metastatic hormonal phenotype but also still seem to
be positively correlated with the primary lesion. These
results were not found for non-visceral metastases and
we can only speculate that probably the different envir-
onment might influence the rate of receptor expression.
In our study, applying the AdnaTest BreastCancer, metas-
tases and CTCs displayed a significantly concordant HER2
status in 67 % of cases whereas no significant concordance
values could be shown for ER and PR. In contrast, applying
the CellSearch® assay, no significant concordance was found
when HER2 status on CTCs was compared to primary tu-
mors and metastases. These findings might be explained by
the different selection strategies of both assays. CellSearch®
as an EpCAM-dependent assay might not detect CTCs that
lost the EpCAM epitope and, therefore might result in false
negatives with regards to HER2 overexpressing cells [41].
In contrast, the AdnaTest CTC enrichment method con-
sists of an antibody mixture targeting EpCAM and MUC1,
which might enable efficient CTC enrichment even in case
EpCAM got lost.
However, CTCs are highly heterogeneous and using
EpCAM-based capturing methods, it has been shown that
this procedure is not able to detect the entire, highly
heterogenous population of CTCs in MBC. In this regard, it
has been demonstrated that these methods underestimate
the most important subpopulations of CTCs involved in
cancer dissemination, which often share EMT and stemness
features [42–45]. In the current study, these subpopulations
have not been analyzed which might explain discordant
findings. Thus, despite the prognostic impact of CTC
counts, molecular methods might complement these studies
by improving the overall detection rate as well as sensitivity
and, thus, permitting the assessment of genomic markers in
CTCs of MBC patients as recently published [46].
From the clinical point of view, in a recent review of the
literature, Turner and Di Leo concluded that the best man-
agement approach for receptor discordance between pri-
mary and metastatic disease is currently unknown, and the
very limited evidence of alteration in clinical outcomes
based on repeated biopsy does not seem to be strong
enough to confirm that repeated biopsy is essential in
every patient [47].
However, although these discrepancies have been dem-
onstrated, the acquisition of tissue from metastases is
not recommended as routine practice in any guideline.
Thus, monitoring and phenotypic characterization of
CTCs can provide new insights into the clonal selection
of tumor cells under palliative therapies which may
allow physicians to follow cancer changes over time and
tailor treatment accordingly.
Conclusion
To the best of our knowledge, this is the first study com-
paring HER2/ER/PR expression profiles of primary tu-
mors, metastases and CTCs. Although we could show
that primary tumors and their metastases showed a highly
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significant concordance of the expression of predictive
markers, monitoring and a more comprehensive pheno-
typic characterization of CTCs will show whether CTCs
can provide new insights into the clonal selection of resist-
ant tumor cells under biological therapies. In this regard,
the DETECT III phase III trial in Germany, comparing
standard therapy alone versus standard therapy plus HER2
targeted therapy in patients with initially HER2-negative
MBC and HER2-positive CTCs will probably answer that
question. In this setting, patients with HER2-positive CTCs
receive a targeted treatment option, noting that CTC de-
tection and HER2 testing is performed by use of the Cell-
Search® assay (www.detetct-studien.de).
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